Dual inhibitors of Janus kinase 2 and 3 (JAK2/3): designing by pharmacophore- and docking-based virtual screening approach
- 11 January 2014
- journal article
- Published by Springer Nature in Molecular Diversity
- Vol. 18 (2) , 253-267
Abstract
JAK2 and JAK3 are non-receptor protein tyrosine kinases implicated in B-cell- and T-cell-mediated diseases. Both enzymes work via different pathways but are involved in the pathogenesis of common lymphoid-derived diseases. Hence, targeting both Janus kinases together can be a potential strategy for the treatment of these diseases. In the present study, two separate pharmacophore-based 3D-QSAR models ADRR.92 ( \(Q_{\mathrm{test}}^{2} 0.663, R^{2}_{\mathrm{train}} 0.849\) , F value 219.3) for JAK2 and ADDRR.142 ( \(Q^{2}_{\mathrm{test}}0.655, R_{\mathrm{train}}^{2}\) 0.869, F value 206.9) for JAK3 were developed. These models were employed for the screening of a PHASE database of approximately 1.5 million compounds; subsequently, the retrieved hits were screened employing docking simulations with JAK2 and JAK3 proteins. Finally, ADME properties of screened dual inhibitors displaying essential interactions with both proteins were calculated to filter candidates with poor pharmacokinetic profiles. These candidates could serve as novel therapeutic agents in the treatment of lymphoid-related diseases.
Keywords
This publication has 36 references indexed in Scilit:
- Discovery of 1-Amino-5H-pyrido[4,3-b]indol-4-carboxamide Inhibitors of Janus Kinase 2 (JAK2) for the Treatment of Myeloproliferative DisordersJournal of Medicinal Chemistry, 2011
- Pyrrolo[1,2-f]triazines as JAK2 inhibitors: Achieving potency and selectivity for JAK2 over JAK3Bioorganic & Medicinal Chemistry Letters, 2011
- Identification of a Potent Janus Kinase 3 Inhibitor with High Selectivity within the Janus Kinase FamilyJournal of Medicinal Chemistry, 2010
- Structural and Thermodynamic Characterization of the TYK2 and JAK3 Kinase Domains in Complex with CP-690550 and CMP-6Journal of Molecular Biology, 2010
- Discovery and SAR of potent, orally available 2,8-diaryl-quinoxalines as a new class of JAK2 inhibitorsBioorganic & Medicinal Chemistry Letters, 2010
- 2-Amino-aryl-7-aryl-benzoxazoles as potent, selective and orally available JAK2 inhibitorsBioorganic & Medicinal Chemistry Letters, 2010
- PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary resultsJournal of Computer-Aided Molecular Design, 2006
- Glide: A New Approach for Rapid, Accurate Docking and Scoring. 1. Method and Assessment of Docking AccuracyJournal of Medicinal Chemistry, 2004
- Mapping the kinase domain of janus kinase 3Bioorganic & Medicinal Chemistry Letters, 2003
- Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathwayBiochemical Journal, 1998